Janssen Receives Positive CHMP Opinions for Novel

Talquetamab is the first therapy targeting GPRC5D to receive a positive CHMP Opinion Teclistamab, the first BCMA-targeting bispecific antibody to...

Related Keywords

Chicago ,Illinois ,United States ,Belgium ,Beerse ,Region Flamande ,United Kingdom ,British ,American ,Sen Zhuang ,Edmond Chan ,Committee For Medicinal Products Human Use ,None Of The Janssen Pharmaceutical Companies ,American Society Of Clinical Oncology ,European Medicines Agency ,European Hematology Association ,Drug Administration ,European Commission ,Janssen Research Development ,Janssen Pharmaceutical Companies Of Johnson ,Exchange Commission ,Clinical Research ,American Cancer Society ,Companies Of Johnson ,Johnson ,Janssen Pharmaceutical Companies ,Medicinal Products ,Human Use ,Senior Director ,Area Lead Haematology ,Clinical Oncology ,Annual Meeting ,Hematology Association ,Hybrid Congress ,Vice President ,Janssen Research ,Breakthrough Therapy Designation ,Orphan Drug Designation ,Pharmaceutical Companies ,Infectious Diseases ,Janssen Cilag Limited ,Private Securities Litigation Reform Act ,Janssen Pharmaceutica ,Janssen Pharmaceutical ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Bispecific Antibody ,Escalation Study ,Participants With Relapsed ,Refractory Multiple Myeloma ,Refractory Multiple ,Teclistamab Each ,Combination With ,Programmed Cell Death ,Study Comparing Talquetamab ,Combination With Daratumumab ,Pomalidomide Versus Daratumumab ,Combination With Pomalidomide ,Subcutaneous Daratumumab Regimens ,Participants With Multiple ,Participants With Multiple Myeloma ,European Medicines ,Bispecifict Cell Redirection Antibodies ,Daratumumab Subcutaneously ,Versus Daratumumab ,Today Population Factsheets ,Janssen Emea ,